EUCTR2008-005059-67-GB进行中（未招募）不适用
A multi-centre, randomised, double blind, placebo-controlled, parallel group, single dose, pilot study of the efficacy of 0.6 mg Amylmetacresol BP (AMC) and 1.2mg 2,4-Dichlorobenzyl alcohol (DCBA) throat lozenges in the relief of sore throat due to upper respiratory tract infection. - 0.6 mg AMC and 1.2 mg DCBA Lozenges Pilot Efficacy Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Age: =18 to =75
- •2)Both male and female patients may be included;
- •3)Primary diagnosis: Patients with sore throat of onset within the past 4 days (i.e. = 4 days)
- •4)Patients who have a sore throat (= 6) on the Throat Soreness Scale at baseline. They will be instructed by the study nurse to swallow and circle the number on the scale that shows how your sore throat is when you swallow. Ratings on this 0-10 ordinal scale will be marked with 0= Not score(besides ‘0’ rating) and 10=Very Sore (beside ’10)
- •5)Objective findings that confirm the presence of tonsillopharyngitis (= 5 points on the expanded 21-point Tonsillopharyngitis Assessment)
- •6)Patients who have given written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Any previous history of allergy or known intolerance to the study drug or the following formulation constituents, AMC, DCBA anise oil, peppermint oil, menthol natural or menthol synthetic, tartaric acid gran 571 GDE, ponceau 4R edicol E124, carmoisine edicol E122, sugar and glucose.
- •2)Those whose sore throat has been present for more than 4 days.
- •3)Those who have evidence of mouth breathing
- •4)Those who have evidence of severe coughing
- •5)Those who have any disease that can compromise breathing e.g. bronchopneumonia.
- •6)Those who have taken any medicated confectionary, throat pastille, spray, or any product with demulcent properties such as boiled sweets in the previous 2 hours.
- •7)Those who have used any sore throat medication containing a local anaesthetic within the past 4 hours.
- •8)Those who have used any analgesic, antipyretic or cold medication (e.g. decongestant, antihistamine, antitussive or throat lozenge) within the previous 8 hours.
- •9)Those who have used a longer acting or slow release analgesic during the previous 24 hours e.g. Piroxicam and Naproxen.
- •10)Those taking antibiotics during the previous 14 days
- •11)Those with any painful condition that may distract attention from sore throat pain e.g. mouth ulcers etc.
- •12)Those with a history of severe renal impairment.
- •13)Those with a history of severe hepatic impairment
- •14)Those taking warfarin and other coumarins
- •15)Those taking carbamezepine, phenobarbitone, phenytoin, primidone, rifampicin, St Johns Wort or other drugs that induce liver enzymes in the 14 days before enrolment into the study (i.e. before first dosing day)
- •16)Those with a history of alcohol abuse or state that they regularly consume alcohol in excess of the recommended amounts (excessive alcohol >21 units per week for females and >28 units per week for males.)
- •17)Those who are glutathione-deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
- •18)Those with any painful condition that requires analgesic usage
- •19)Those unable to refrain from smoking during their stay in the investigative site
- •20)Women of childbearing potential , who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch or an intrauterine device. A women of child bearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone an hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy)
- •21)Those previously randomised into the study
- •22)Those who have participated in a clinical trial in the previous 30 days. Thirty days are calculated from time of last dosing in the prior trial to time of anticipated dosing in this trial.
- •23)Those unable in the opinion of the investigator to comply fully with the study requirements, e.g. such as those who cannot comprehend or correctly use the pain rating scales.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate the effects of a product, fibrinogen concentrate, to assist with rapid clotting of the blood, in patients with major bleeding caused by trauma.Trauma patients whereby the local major haemorrhage protocol has been activatedMedDRA version: 18.0 Level: LLT Classification code 10044461 Term: Trauma System Organ Class: 100000004863EUCTR2015-000875-28-GBHS Blood & Transplant48
进行中（未招募）
2 期
Evaluate the effectiveness and safety of Cpn10 in subjects with moderate to severe rheumatoid arthritis despite treatment with methotrexateACTRN12608000208303CBio Limited150
已完成
2 期
A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren*s DiseaseNL-OMON47684niversity of Oxford, Research Services, Clinical Trials and Research Governance, Joint Research Office, Boundary Brook House35
进行中（未招募）
1 期
Repurposing anti-TNF for treating Dupuytren’s disease.EUCTR2015-001780-40-GBniversity of Oxford, Clinical Trials and Research Governance228
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, placebo-controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven®) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypassheart disease/cardiac surgeryMedDRA version: 6.1Level: PTClassification code 10061026EUCTR2004-000100-40-GBovo Nordisk A/S5,000